The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the opportunity for more-effective alternatives—in particular, disease-modifying therapies (DMTs) that can slow the course of the disease. In response, drug developers—from big pharma to small biotech—continue to invest heavily in disease-modifying approaches due to the tremendous clinical and commercial opportunity in this arena, despite decades of late-phase failures. While, many uncertainties remain about the approval prospects for Biogen / Eisai’s aducanumab, and the fate of anti-amyloid MAbs from Eisai / Biogen (BAN2401) and Roche (gantenerumab) in their ongoing Phase III trials, key opinion leaders (KOLs) are cautiously optimistic about the anti-tau therapies (approximately 15) in early- to mid-phase trials, and hope remains for the late-phase therapies from Lundbeck / Otsuka, Avanir / Otsuka, and Acadia that are in development for the treatment of AD agitation and psychosis, respectively. Ultimately, however, the launch of any of these is far from guaranteed.


  • What are the drivers and constraints in the AD market?
  • How large is the treatable AD population? What commercial uptake can be expected from Rexulti, AVP-786, and Nuplazid should they launch?
  • What will be the impact of DMTs—should any of them launch—on diagnosis, drug treatment, and revenue, and which populations will be most affected?
  • What are the key learning points from the recent failure of late-phase anti-amyloid therapies, and what are experts’ opinions of the launch prospects for agents still in development?


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key findings
      • Alzheimer's Disease Key Findings - July 2020
    • Key Updates
      • July 2020
        • July 2020
      • May 2020
      • October 2019
      • September 2019
      • June 2019
    • Market Outlook
      • Key Findings
      • COVID-19: Areas of Potential Forecast Impact
        • COVID-19: Areas of Potential Forecast Impact
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Alzheimer's Disease?
        • What Factors Are Constraining the Market for Alzheimer's Disease?
      • Drug-Class-Specific Trends
        • Acetylcholinesterase Inhibitors
        • NMDA Receptor Antagonists
        • Donepezil / Memantine Fixed-Dose Combinations
        • Behavioral Therapies
      • Alternative Market Scenarios
        • Disease-Modifying Therapies
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Overview
      • Etiology
      • Pathophysiology
      • Disease Progression/Natural History
      • Key Pathways and Drug Targets
        • Key Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Total Prevalent Cases of AD
        • Total Prevalent Cases of AD by Severity
        • Total Ten-Year Prevalent Cases of Pre-AD
        • Diagnosed Prevalent Cases of AD by Symptom Status
        • Diagnosed Prevalent Cases of Symptomatic Pre-AD and AD by Severity
        • Drug-Treated Cases of Symptomatic Pre-AD and AD by Severity
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview of Alzheimer's Disease Drug Classification
        • Acetylcholinesterase Inhibitors
        • NMDA Receptor Antagonists
        • Antipsychotics
        • Antidepressants
        • Current Diagnostics
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Alzheimer's Disease
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Drug Development and Regulatory Hurdles
        • Disease-Modifying Therapies
        • Antipsychotics
        • NMDA Receptor Modulators
        • AChEI Reformulations
        • Other Notable Compounds in Late-Phase Development for Alzheimer's Disease
        • Prominent Late-Phase Failures in AD
      • Early-Phase Pipeline Analysis
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Alzheimer's Disease Bibliography

Author(s): Meher Baba Kumar Nakka, M.S. (Pharm.); Fjoralba Kristo, MD, MPH; Ruchita Kumar, Ph.D

Meher Baba Kumar Nakka, (Pharm.) is an analyst on the CNS/Ophthalmology team. In this role he works and keeps track on a range of neurological indications such as pain, migraine, including neurodegenerative disorders like AD etc. To his role at DRG, Meher brings 5 years of experience in supporting global commercial strategy by providing comprehensive solutions encompassing competitive intelligence, opportunity assessment, disease narratives, literature review and ad-hoc customized searches across healthcare sectors such as pharmaceutical/bio-pharmaceuticals and Medical devices. He holds a Bachelors degree in Pharmacy from JNTU, Hyderabad and a Masters degree in Pharmacoinformatics from NIPER, Mohali.

Fjoralba Kristo has expertise in forecasting infectious diseases and chronic diseases in both the mature and global markets. She has extensive academic experience with quantitative and qualitative research methods. Prior to joining Decision Resources Group, she completed a postdoctoral fellowship at University of Kentucky, Division of Cardiovascular Medicine, and more recently worked as Research Scientist at Massachusetts General Hospital, where she investigated mechanisms of inflammation in cardiovascular diseases. Fjoralba holds an MPH degree from Boston University School of Public Health, concentrating in Epidemiology and Biostatistics, and a medical degree from University of Medicine, Bucharest, Romania.

Ruchita has joined as a Lead Analyst in the Central Nervous System and Ophthalmology team at Decision Resources Group. She comes with eight years of experience in handling various types of commercial assessment projects. She has worked on variety of opportunity assessment and market intelligence projects involving preparation of disease narratives, epi-based forecasts, patent landscapes, social media analysis and building brand performance reports across different therapy areas. She earned a in design and development of modified release dosage forms of anti-diabetic drugs from the University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh.

Related Reports

Alzheimer's Disease | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

For the estimated 3.4 million people in the United States with Alzheimer’s disease (AD), approved pharmacotherapy is limited to four procognitive symptomatic agents (e.g., donepezil, memant...

View Details

Alzheimer's Disease | Disease Landscape and Forecast | G7 | 2019

The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the oppo...

View Details

Alzheimer's Disease | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Alzheimer’s dise...

View Details